Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2021-12-02 Report Publication Anno…
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Report Publication Announcement Classification · 98% confidence The document is a press release dated December 2, 2021, announcing the upcoming videoconference and publication of the '2021-2022 Half-Year Results' scheduled for December 8, 2021. It explicitly states that the 'Half-Year Financial report will be available' on specific websites. Since the document itself is an announcement about the release of a financial report (which covers a period shorter than a year, ending September 30, 2021) rather than the comprehensive report itself, it fits the definition of a Report Publication Announcement (RPA). The document length (2267 chars) is short, supporting the RPA classification over the full Interim Report (IR) classification.
2021-12-02 English
Inside Information / Other news releases
Capital/Financing Update Classification · 99% confidence The document is a press release dated December 1, 2021, announcing that MedinCell has received €4 million in funding from Bpifrance and the French Recovery Plan. The content focuses entirely on securing financing (€3 million loan and €1 million grant) for R&D and site expansion. This directly relates to fundraising and capital structure changes. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as the primary subject is the successful acquisition of new funds.
2021-12-01 English
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document announces that MedinCell has secured financing totaling 4 million euros from Bpifrance, split into a 3 M€ loan for a long-acting drug development program (mdc-TTG) and a 1 M€ grant for a new laboratory under the France Relance plan. This clearly relates to fundraising, financing activities, and capital structure support for R&D and growth. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it mentions a future 'présentation des résultats semestriels', the primary focus and content of this specific release is the financing event itself. The document length (3131 chars) is substantial enough to be a primary announcement, not just a brief RPA.
2021-12-01 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights). It provides a table detailing the number of shares and voting rights as of October 31, 2021, and references the AMF (Autorité des Marchés Financiers) regulations. This content directly relates to changes in share capital and voting rights, which aligns with the definition of Share Issue/Capital Change (SHA) or potentially a Major Shareholding Notification (MRQ) if it were about crossing thresholds, but the primary focus is the monthly count of total shares and votes. Given the options, 'Share Issue/Capital Change' (SHA) is the closest fit for reporting the total capital structure components monthly, although it is a very specific type of capital disclosure. However, looking closely at the definitions, 'Major Shareholding Notification' (MRQ) is for changes in *significant* ownership levels (crossing thresholds). Since this document reports the *total* capital and voting rights, it is a fundamental disclosure about the capital structure. In many regulatory contexts, this type of monthly capital update is often grouped with capital changes or specific regulatory disclosures. Since there is no specific code for 'Monthly Capital Disclosure', and it is a formal regulatory filing (AMF reference), I will check the closest fit. SHA covers 'New share issues, stock splits, or other capital changes'. This is a report on the current state of capital. If we consider the options, this is a disclosure about the capital base. Let's re-evaluate the options. It is not a Director's Dealing (DIRS), nor a Dividend Notice (DIV). It is a mandatory disclosure about the total number of shares and voting rights. This type of filing is often categorized under capital structure updates. SHA seems the most appropriate category among the provided choices for a report detailing the total number of shares and voting rights, as it pertains directly to the capital structure.
2021-11-03 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release dated November 1, 2021, announcing positive Phase 3 clinical trial results for a drug candidate (mdc-IRM/TV46000) and detailing upcoming conference calls for shareholders and the financial community to discuss these results. It contains key financial/development milestones, quotes from management, and forward-looking statements typical of corporate news. Since it is an initial announcement of key financial/development results (Phase 3 data) rather than the full, comprehensive report (like a 10-K or IR), it fits best as an Earnings Release (ER), even though the content is clinical trial data rather than quarterly revenue figures. It is a high-level announcement of a major corporate/product milestone. It is not a transcript (CT), a formal annual report (10-K), or a simple announcement of a report publication (RPA). FY 2021
2021-11-01 French
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is dated November 1, 2021, and announces key outcomes from a Phase 3 clinical trial (RISE study) for a product (mdc-IRM/TV-46000) developed with Teva. It details efficacy and safety results, mentions upcoming conference calls for shareholders, and includes standard forward-looking statements and contact information typical of a press release announcing significant operational/clinical news. This structure strongly indicates an initial announcement of financial or operational results, which aligns best with the 'Earnings Release' (ER) category, even though the results are clinical rather than purely financial figures. Since it is a comprehensive announcement of results intended for the financial community, it is classified as ER. It is not a full 10-K, an IR, or a simple RPA. FY 2021
2021-11-01 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.